A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity

British Journal of Pharmacology

Volumn 146, Issue 3, 2005, Pages 333-343

  Takahashi, Hidenori ^a   Ebihara, Satoru ^a   Okazaki, Tatsuma ^a   Asada, Masanori ^a   Sasaki, Hidetada ^a   Yamaya, Mutsuo ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; Cancer; Heparanase; Heparins; Vascular endothelial growth factor

Indexed keywords

BLOOD CLOTTING FACTOR 10; DALTEPARIN; DANAPAROID; HEPARANASE; HEPARIN; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; SOLID TUMOR; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; ANTICOAGULANTS; BLEEDING TIME; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHONDROITIN SULFATES; DALTEPARIN; DERMATAN SULFATE; ENDOTHELIAL CELLS; FACTOR X; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GLUCURONIDASE; HEPARIN; HEPARITIN SULFATE; HUMANS; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; RNA, MESSENGER; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 27144534062     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706344     Document Type: Article

References (27)

1. BIJSTERVELD, N.R., HETTIARACHCHI, R.J.K., PETERS, R., PRINS, M.H., LEVINE, M. & BÜLLER, H.R. (1999). Low-molecular weight heparins in venous and arterial thrombotic disease. Thromb. Haemost., 82 (Suppl 2), 139-147.
2. CARMELIET, P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nat. Med., 6, 389-395.
3. CARMELIET, P. & JAIN, R.K. (2000). Angiogenesis in cancer and other diseases. Nature, 407, 249-257.
4. ELKIN, M., ILAN, N., ISHAI-MICHAELI, R., FRIEDMANN, Y., PAPO, O., PECKER, I. & VLODAVSKY, I. (2001). Heparanase as mediator of angiogenesis: mode of action. FASEB J., 15, 1661-1663.
5. EL-SHEIKH, A., LIU, C., HUANG, H. & EDGINGTON, T.S. (2002). A novel vascular endothelial growth factor heparin-binding domain substructure binds to glycosaminoglycans in vivo and localizes to tumor microvascular endothelium. Cancer Res., 62, 7118-7123.
6. FERRARA, N. (2002). VEGF and the quest for tumor angiogenesis factors. Nat. Rev. Cancer, 2, 795-803.
7. FERRARA, N., GERBER, H.P. & LE-COUTER, J. (2003). The biology of VEGF and its receptors. Nat. Med., 9, 669-676.
8. FOLKMAN, J. & SHING, Y. (1992). Control of angiogenesis by heparin and other sulfated polysaccharides. Adv. Exp. Med. Biol., 313, 355-364.
9. GOLDSHMIDT, O., ZCHARIA, E., ABRAMOVITCH, R., METZGER, S., AINGORN, H., FRIEDMANN, Y., SCHIRRMACHER, V., MITARI, E. & VLODAVSKY, I. (2002). Cell surface expression and secretion of heparanase markedly promote tumor angiogenesis and metastasis. Proc. Natl. Acad. Sci. U.S.A., 99, 10031-10036.
10. HEJMA, M., RADERER, M. & ZIELINSKI, C.C. (1999). Inhibition of metastases by anticoagulants. J. Natl. Cancer Inst., 91, 22-36.
11. HETTIARACHCHI, R.J.K., SMORENBERG, S.M., GINSBERG, J., LEVINE, M., PRINS, M.H. & BÜLLER, H.R. (1999). Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread. Thromb. Haemost., 82, 947-952.
12. HIRSH, J., WARKENTIN, T.E., SHAUGHNESSY, S.G., ANAND, S.S., HALPERIN, J.L., RASCHKE, R., GRANGER, C., OHMAN, E.M. & DALEN, J.E. (2001). Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest, 119 (Suppl 1), 64S-94S.
13. KANDA, A., EBIHARA, S., TAKAHASI, H. & SASAKI, H. (2003). Loxoprofen sodium suppresses mouse tumor growth by inhibiting vascular endothelial growth factor. Acta Oncol., 42, 62-70.
14. LEVER, R. & PAGE, C.P. (2002). Novel drug development opportunities for heparin. Nat. Rev. Drug Discov., 1, 140-148.
15. LEVI, M. & TEN CATE, H. (1999). Disseminated intravascular coagulation. N. Engl. J. Med., 19, 586-592.
16. MEULEMAN, D.G. (1992). Orgaran (ORG 10172): its pharamacological profile in experimental models. Haemostasis, 22, 58-65.
17. NORRBY, K. (1993). Heparin and angiogenesis: a low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogenesis systemically. Haemostasis, 23, 141-149.
18. OKAJIMA, K., SAKAMOTO, Y. & UCHIDA, M. (2000). Heterogeneity in the incidence and clinical manifestations of disseminated intravascular coagulation: a study of 204 cases. Am. J. Hematol., 65, 215-222.
19. PARISH, C.R., COOMBE, D.R., JAKOBSEN, K.B., BENNETE, F.A. & UNDERWOOD, P.A. (1987). Evidence that sulphated polysaccharides inhibit tumor metastasis by blocking tumor-cell-derived heparanases. Int. J. Cancer, 40, 511-518.
20. PASSANITI, A., TAYLOR, R.M., PILI, R., GUO, Y., LONG, P.V., HANEY, J.A., PAULY, R.R., GRANT, D.S. & MARTIN, G.R. (1992). A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest., 67, 519-528.
21. PIEPER, J.S., HAFMANS, T., VAN WACHEM, P.B., VAN LUYN, M.J., BROUWER, L.A., VEERKAMP, J.H. & VAN KUPPEVELT, T.H. (2002). Loading of collagen-heparan sulfate matrices with bFGF promotes angiogenesis and tissue generation in rats. J. Biomed. Mater. Res., 62, 185-194.
22. SALLAH, S., WAN, J.Y., NGUYEN, N.P., HANRAHAN, L.R. & SIGOUNAS, G. (2001). Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thromb. Haemost., 86, 828-833.
23. SMORENBURG, S.M. & VAN NOORDEN, C.J.F. (2001). The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol. Rev., 53, 93-105.
24. TAKAHASHI, H., EBIHARA, S., OKAZAKI, T., SUZUKI, S., ASADA, M., KUBO, H. & SASAKI, H. (2004). Clinical significance of heparanase activity in primary resected non-small cell lung cancer. Lung Cancer, 45, 207-214.
25. TARDY-PONCET, B., TARDY, B., REYNAUD, J., MAHUL, P., MISMETTI, P., MAZET, E. & GUYOTAT, D. (1999). Efficacy and safety of danaparoid (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia. Chest, 115, 1616-1620.
26. VOLDAVSKY, I. & FRIEDMANN, Y. (2001). Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J. Clin. Invest., 108, 341-347.
27. WEIDNER, N., SEMPLE, J.P., WELCH, W.R. & FOLKMAN, J. (1991). Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N. Engl. J. Med., 324, 1-8.